Dr. Will Gibson and Dr. C. Michael Gibson discuss how p53 was once considered an undruggable target for cancer therapy.
A new article in the NEJM raises hope that there may be a path forward. Dr. Will Gibson, an oncologist at […]
Clinical Trial Results
A new article in the NEJM raises hope that there may be a path forward. Dr. Will Gibson, an oncologist at […]
We talk about the importance of MDs reviewing AI output and the timing of CT reassessment of risk Sponsored by […]
Sponsored by Cleerly, Women as One and International Atherosclerosis Society.
In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by […]
Sponsored by Cleerly, Women as One and International Atherosclerosis Society